News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Nov 05, 2002
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, is today announcing preliminary results from its first four completed Phase III clinical trials.
Sep 30, 2002
GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces the latest Phase II data from a completed 34 patient study in patients with Mu
Aug 29, 2002
Dr Geoffrey Guy, Executive Chairman of GW Pharmaceuticals, said: "Progress across the breadth of the Group's activities has continued according to expectation in the first half of the financial year and GW's develop
Apr 11, 2002
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, announces the commencement of Phase Three clinical trials in four new indications.
Feb 18, 2002
GW Pharmaceuticals plc has welcomed the Government's statement that it will ask the National Institute for Clinical Excellence (NICE) to examine the possible provision of the Company's medicines by the National Heal
Feb 05, 2002
To view this report please clic
Jan 16, 2002
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that it has expanded its Phase Three clinical trials programme into cancer pain.
Jan 16, 2002
GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces its first set of preliminary results since flotation on the Alternative Invest